Generic Name and Formulations:
Bethanechol chloride 5mg, 10mg, 25mg, 50mg; scored tabs.
Indications for URECHOLINE:
Post-op and post-partum nonobstructive urinary retention and retentive neurogenic urinary atony.
Take on empty stomach. Initially 5–10mg every hour until effective or max 50mg, then 10–50mg 3–4 times daily.
Hyperthyroidism. Peptic ulcer. Asthma. Bradycardia. Hypotension. Vasomotor instability. Coronary artery disease. Epilepsy. Parkinsonism. Obstructive uropathies. Questionable GI or bladder integrity. Obstructive, spastic, inflammatory GI disorders. Vagotonia. Peritonitis. When increased GI or bladder muscle activity may be harmful.
Reflux urinary infection. Pregnancy (Cat.C). Nursing mothers: not recommended.
Severe abdominal symptoms and hypotension with ganglionic blockers.
Cholinergic effects, GI upset, asthma, headache, facial flushing, malaise, orthostatic hypotension.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|